Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison

Archives of Neurology

Volumn 58, Issue 6, 2001, Pages 944-950

  Spierings, Egilius L H ^a,d   Gomez Mancilla, Baltazar ^b   Grosz, Daniel E ^c   Rowland, Clayton R ^b   Whaley, Fredrick S ^b   Jirgens, Kathleen J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c Pharmacology Research Institute   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; SUMATRIPTAN SUCCINATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYNCOPE; TACHYCARDIA; THORAX PAIN;

EID: 0034970004     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.6.944     Document Type: Article

References (13)

1. Almotriptan
2. Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine
3. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug
4. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study
5. Oral almotriptan in the treatment of migraine: A dose finding study
6. 1B/1D agonist
7. Optimum-dose determination of the triptans
8. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
9. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
10. 2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs
11. Coronary side-effect potential of current and prospective antimigraine drugs
12. 1D agonist, in patients with acute migraine